AC
OACCU

Athos Capital’s Oaktree Acquisition Corp III Life Sciences Unit OACCU Stock Holding History

Athos Capital’s Portfolio OACCU Stock Details OACCU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$534K Hold
50,000
– – 0.16% 28
2025
Q4 		$536K Hold
50,000
– – 0.21% 23
2025
Q3 		$533K Hold
50,000
– – 0.33% 18
2025
Q2 		$531K Hold
50,000
– – 0.79% 20
2025
Q1 		$522K Hold
50,000
– – 0.62% 28
2024
Q4 		$507K Buy
+50,000
New +$504K 0.23% 23

Other funds holding OACCU

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return

Athos Capital's OACCU Position: Q1 2026 in Review

Athos Capital held its Oaktree Acquisition Corp III Life Sciences Unit (OACCU) position steady in Q1 2026 at 50,000 shares worth $534K. The position accounts for 0.16% of the portfolio, ranked #28.

Athos Capital first reported a position in OACCU in Q4 2024 and has held it in 6 quarters since. The position peaked at $536K in Q4 2025. 6 funds tracked by Wall St. Rank hold OACCU as of Q1 2026.

  • Athos Capital held 50,000 shares of Oaktree Acquisition Corp III Life Sciences Unit worth $534K as of Q1 2026.
  • Athos Capital left its Oaktree Acquisition Corp III Life Sciences Unit share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences Unit made up 0.16% of Athos Capital's portfolio in Q1 2026, its #28 holding.
  • Athos Capital first reported a position in Oaktree Acquisition Corp III Life Sciences Unit in Q4 2024 and has held it in 6 quarters since.
  • Athos Capital's Oaktree Acquisition Corp III Life Sciences Unit position peaked at $536K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Unit as of Q1 2026.

Based on Athos Capital's 13F filing for Q1 2026, filed 13 May 2026.